Mihir Jain: Can Gene Therapy Transform Hemophilia Care in India?
Mihir Jain, MBBS graduate from Government Medical College and Hospital (GMCH), Chandigarh, shared a post on LinkedIn:
“Can gene therapy transform hemophilia care in India?
I recently completed an independent healthcare strategy project exploring the commercial and market access landscape for hemophilia gene therapy in India.
The project combines my medical background with data-driven analysis to evaluate:
- Market opportunity
- Patient population and treatment landscape
- Access and reimbursement challenges
- Competitive environment
- Strategic considerations for commercialization
The project includes:
As an MBBS graduate, I’m building a portfolio at the intersection of healthcare consulting, life sciences strategy, medical affairs, pharmacovigilance, and data analytics by tackling real-world industry questions.
I welcome feedback and would be glad to connect with professionals working in healthcare consulting, pharma, biotech, and life sciences.”
Stay updated with Hemostasis Today.
-
Sep 4, 2026, 22:01Lama Skieker: Understanding Thrombocytopenia in Malaria
-
Sep 4, 2026, 22:00Hiten Patel: How an IVC Filter Helps Prevent Pulmonary Embolism
-
Sep 4, 2026, 21:54Gianluca Costamagna: Investigating the Link Between Cancer and Acute Ischemic Stroke
-
Sep 4, 2026, 21:50Ben Creagh-Brown: PRAGUE-26 and HI-PEITHO Similar Benefits With Important Differences
-
Sep 4, 2026, 21:48Jin-Xiong She: Homocysteine beyond Heart Disease – The Methylation-Mobility Connection
-
Sep 4, 2026, 21:44Aravind Palraj: Anemia of Chronic Inflammation is Not Just “Iron Deficiency”
-
Sep 4, 2026, 21:41Chokri Ben Lamine: Fundamental HSCT Workshop for Hematology Fellows at HAAG 2026
-
Sep 4, 2026, 21:39Pierre Sabouret: A Good Surprise Our New Publication in Life Is Online
-
Sep 4, 2026, 21:37Maria Queralt Gorgas: Treating AF With Intermediate Stroke Risk With Anticoagulation